TickerGuard
Buy Day today: Neutral (56) Mixed market breadth · no major macro event
ICCC

ImmuCell Corporation

Healthcare · Biotechnology

10.60$ +2.9% vs. previous close Closing price · As of: Nov 2, 2026

Ownership

Ownership Structure

Who owns ImmuCell Corporation (ICCC)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 66.4% of the shares are freely tradable; institutional investors hold 21.7%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 21.7%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 32.1%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 66.4%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 0.3%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 9Mio.

Largest Shareholders

Institutions

Institutions ICCC
Name Stake (%) Shares Change (%) Date
Vanguard Capital Management, LLC 2.95 268,130 +3.0 06/30/2026
Morgan Stanley - Brokerage Accounts 2.58 233,910 +5.5 06/30/2026
Renaissance Technologies Corp 1.88 171,089 +12.7 06/30/2026
Cresset Asset Management, LLC 1.49 135,267 +0.0 06/30/2026
Geode Capital Management, LLC 0.80 72,270 +9.9 06/30/2026
Dimensional Fund Advisors, Inc. 0.64 58,452 +4.3 06/30/2026
Bleichroeder LP 0.55 50,000 -50.8 06/30/2026
Steadtrust LLC 0.50 45,370 -16.6 06/30/2026
Mesirow Fin Investmt Mgmt Intl Equity 0.47 42,481 +0.0 06/30/2026

Funds

Funds ICCC
Name Stake (%) Shares Change (%) Date
Vanguard MStar Total Stk Mkt Idx Invest 1.99 181,077 +0.0 09/30/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Data as of: November 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?